Description
Dapagliflozin and Metformin Hydrochloride Extended-Release (XR) Tablets are a fixed-dose combination oral medication used in the management of Type 2 Diabetes Mellitus (T2DM). This formulation combines dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, with metformin hydrochloride, a biguanide, in an extended-release form to enhance glycemic control while minimizing dosing frequency and gastrointestinal side effects.
Mechanism of Action:
Dapagliflozin:
- Selectively inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption.
- Leads to increased urinary glucose excretion (glycosuria), reducing blood glucose levels.
- Also contributes to modest weight loss and blood pressure reduction.
Metformin (Extended-Release):
- Suppresses hepatic gluconeogenesis (glucose production).
- Increases insulin sensitivity in muscle and adipose tissue.
- Decreases intestinal absorption of glucose.
- Its extended-release formulation ensures prolonged therapeutic effect and reduced gastrointestinal side effects.
Uses:
Improve blood sugar control in adults with T2DM when:
- Diet and exercise alone are not sufficient
- Monotherapy with metformin or dapagliflozin is inadequate
- Dual therapy is clinically appropriate as initial treatment
Initial combination therapy in patients with high blood glucose levels needing rapid glycemic control.
